2024-11-18 - Analysis Report
## AbbVie Inc. (ABBV) Stock Report

This report analyzes AbbVie Inc. (ABBV) based on the provided data.  Note that this analysis is based solely on the information provided and may not encompass all relevant factors for a complete investment decision.  Independent research is strongly recommended.

**1. Performance Comparison & Divergence:**

AbbVie's cumulative return (144.9%) significantly outperforms the S&P 500's (VOO) cumulative return (123.86%) by 21.04 percentage points. This places ABBV's performance at the 40.33rd percentile of its historical divergence from the S&P 500, based on a range of -31.11% to 98.19%.  AbbVie Inc. is a biopharmaceutical company researching, developing, and globalizing medicines and products.

**Alpha and Beta Analysis:**

The provided data shows that AbbVie's alpha (a measure of excess return relative to the benchmark) has fluctuated between -21.2% and 83.8%, indicating periods of both outperformance and underperformance compared to the S&P 500.  Beta (a measure of volatility relative to the benchmark) has consistently declined from 1.0 to 0.3 over the past several years, suggesting decreasing market sensitivity.  CAGR (Compound Annual Growth Rate) varies considerably, reflecting market conditions and company-specific events.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 63.2% | 22.2% | 24.8% | 1.0 | 170.9 |
| 2016-2018  | 79.0% | 27.3% | 46.7% | 1.0 | 162.9 |
| 2017-2019  | 61.4% | 30.2% | 9.7% | 1.1 | 156.5 |
| 2018-2020  | 26.1% | 33.4% | -21.2% | 0.8 | 189.3 |
| 2019-2021  | 77.3% | 33.4% | -22.7% | 0.7 | 239.3 |
| 2020-2022  | 107.4% | 33.4% | 83.8% | 0.6 | 285.6 |
| 2021-2023  | 66.5% | 20.4% | 31.6% | 0.4 | 273.9 |
| 2022-2024  | 36.5% | 20.4% | 8.6% | 0.3 | 299.8 |


**2. Recent Price Movement:**

* **Closing Price:** $164.99 (Last market: $165.02)
* **5-Day Moving Average:** $170.10
* **20-Day Moving Average:** $189.13
* **60-Day Moving Average:** $191.75

The stock is currently trading below all three moving averages, suggesting a possible downward trend.

**3. Technical Indicators & Expected Return:**

* **RSI (27.94):**  Indicates the stock is in oversold territory, potentially suggesting a bounce.
* **PPO (-2.01):**  Negative value suggests bearish momentum.
* **Relative Strength Change (20-day):** -28.15%, signifying a recent downward trend.
* **Expected Return (2+ years):** 24.15% above the S&P 500.  This is a long-term projection and not a guaranteed outcome.

The current price ($165.02) is not significantly different from the closing price to suggest any abrupt price movement.

**4. Recent Earnings Performance:**

AbbVie has consistently exceeded or met EPS expectations in recent quarters.  The most recent quarter (2024-10-30) shows a slight beat of actual EPS (3) over the estimated EPS (2.92).

| Date       | EPS   | Expected EPS |
|------------|-------|--------------|
| 2024-10-30 | 3     | 2.92         |
| 2024-07-25 | 2.65  | 2.57         |
| 2024-04-26 | 2.31  | 2.26         |
| 2024-02-02 | 2.79  | 2.76         |
| 2023-10-27 | 2.95  | 2.86         |


**5. Financial Information:**

* **Revenue and Profitability:** Shows relatively stable revenue but fluctuating profit margins.  Profit margins have decreased in the last two quarters.

| Quarter    | Revenue     | Profit Margin |
|------------|-------------|---------------|
| 2024-09-30 | $14.46B     | 70.87%        |
| 2024-06-30 | $14.46B     | 70.94%        |
| 2024-03-31 | $12.31B     | 66.74%        |
| 2023-12-31 | $14.30B     | 60.11%        |
| 2023-09-30 | $13.93B     | 53.44%        |

* **Capital and Profitability:**  ROE (Return on Equity) shows significant variation, suggesting potential shifts in capital allocation or profitability drivers.

| Quarter    | Equity    | ROE      |
|------------|-----------|----------|
| 2024-09-30 | $6.03B    | 25.88%   |
| 2024-06-30 | $6.78B    | 20.21%   |
| 2024-03-31 | $8.01B    | 17.10%   |
| 2023-12-31 | $10.36B   | 7.93%    |
| 2023-09-30 | $12.09B   | 14.70%   |


**6. News and Recent Issues:**

*(This section requires information from sources like Shacknews and Finbold which were not provided.  Please provide relevant news articles for a complete analysis.)*

**7.  Analyst Opinions and Performance Highlights:**

*(This section requires additional information from financial news sources and analyst reports to provide insights into current market outlook, analyst opinions, and performance highlights.  Please provide relevant data.)*


**8. Overall Summary:**

AbbVie has demonstrated strong historical performance, exceeding the S&P 500 significantly. However, recent price action suggests a possible downward trend, supported by technical indicators like RSI and PPO. While the company has consistently met or exceeded earnings expectations, profit margins and ROE have shown some volatility.  A complete assessment requires analysis of recent news, analyst opinions, and a deeper dive into the company's long-term growth prospects.  The expected long-term outperformance relative to the S&P 500 should be viewed with caution as this is simply a projection.

**9. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  Investing in the stock market involves risk, and you could lose money.  Consult with a qualified financial advisor before making any investment decisions.  This analysis is incomplete without the missing information from sections 6 and 7.
